



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 60323

Title: Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report

Reviewer's code: 05220617

Position: Peer Reviewer

Academic degree: PhD

Professional title: Doctor

Reviewer's Country/Territory: Austria

Author's Country/Territory: China

Manuscript submission date: 2020-10-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-10-31 10:12

Reviewer performed review: 2020-10-31 10:35

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The case report "Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t (11;14) A case report" by Yang et al. is interesting, as it covers a disease with high medical need. The treatment of the patient is very interesting for the field, however, it is not well described - e.g. the patient was 52 at first diagnosis, is now 57, but in the discussion she is 62. It is not well described, why which regimen was chosen (e.g. why RD/VRD alternatively as maintenance therapy), side effects are not always reported and it is not described, if the patient was re-evaluated for changes in cytogenetics or molecular alterations. Moreover, it is not described, why this patient never received carfilzomib or pomalidomid. In a summary, the case is interesting, the topic is of high importance, but the case report is unfortunately written in not sufficient manner to describe all aspects of this highly interesting case.